Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
Status:
Terminated
Trial end date:
2019-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the
treatment of VTE in cancer patients in comparison to the standard treatment with low
molecular weight heparin (LMWH).
Tumor patients with active cancer and newly diagnosed thromboembolic events are randomised to
receive either Rivaroxaban or the standard treatment with low-molecular heparin.